论文信息 - Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand? - 字舞流文

Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?

P. Feugier | S. Leprêtre | R. Letestu | E. W. Van Den Neste | L. Ysebaert | C. Dartigeas | T. Aurran‐Schleinitz | E. Van Den Neste | T. Aurran-Schleinitz